Radiopharm Theranostics (RDPTF) Assets (2024 - 2026)

Radiopharm Theranostics (RDPTF) has reported Assets for 3 consecutive years, with $426559.5 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets fell 22.98% year-over-year to $426559.5 in Q2 2026; TTM through Jun 2026 was $426559.5, a 22.98% decrease from a year earlier, with the FY2026 full-year figure at $408403.1, down 99.53% from the prior year.
• Assets was $426559.5 for Q2 2026 at Radiopharm Theranostics, down from $553858.6 in the prior quarter.
• Over five years, Assets peaked at $92.5 million in Q4 2024 and troughed at $426559.5 in Q2 2026.
• A 3-year average of $23.5 million and a median of $514297.9 in 2024 frame the typical range for Assets.
• Across the five-year window, Assets gained 16.67% in 2025 and decreased 22.98% in 2026, its largest moves.
• Over 3 years, Assets stood at $92.5 million in 2024, then sank by 99.4% to $553858.6 in 2025, then decreased by 22.98% to $426559.5 in 2026.
• The last three Assets figures came in at $426559.5 (Q2 2026), $553858.6 (Q2 2025), and $92.5 million (Q4 2024), per Business Quant data.